Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda symbols : Nvsef save search
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
Published: 2023-12-11 (Crawled : 13:00) - globenewswire.com
ERAS | $1.79 0.0% 570K
|
|
| O: 1.07%
H: 0.0%
C: -2.65%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.75%
H: 0.55%
C: 0.27%
fda melanoma granted designation advanced
FDA Approves Bio-Thera Solutions' Avzivi® (bevacizumab-tnjn), a biosimilar referencing Avastin®
Published: 2023-12-07 (Crawled : 00:00) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.97%
H: 0.3%
C: -0.19%
avzivi fda biosimilar
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
Published: 2023-12-06 (Crawled : 00:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.52%
H: 0.18%
C: -0.43%
fabhalta fda first approval offering novartis
FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade
Published: 2023-10-31 (Crawled : 21:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 2.52%
H: 0.04%
C: 0.04%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.16%
H: 0.7%
C: 0.57%
cosentyx fda treatment novartis
Sandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis
Published: 2023-08-25 (Crawled : 06:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.67%
H: 0.37%
C: 0.26%
tyruko fda biosimilar approval sclerosis
US FDA approves expanded indication for Novartis Leqvio® (inclisiran) to include treatment of adults with high LDL-C and who are at increased risk of heart disease
Published: 2023-07-10 (Crawled : 12:00) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 1.44%
H: 0.73%
C: 0.48%
leqvio fda disease treatment risk novartis heart
Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation
Published: 2023-03-21 (Crawled : 15:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.89%
H: 0.0%
C: -1.15%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.25%
H: 0.19%
C: 0.04%
hyrimoz fda biosimilar approval
Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer
Published: 2023-03-16 (Crawled : 23:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.02%
H: 0.39%
C: -0.69%
fda approved tafinlar cancer novartis
FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy
Published: 2023-03-16 (Crawled : 07:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.16%
H: 0.73%
C: 0.73%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.18%
H: 0.77%
C: 0.64%
illuccix fda therapy
Sandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDA
Published: 2023-02-06 (Crawled : 07:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.44%
H: 0.0%
C: -2.93%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.33%
H: 0.15%
C: -0.12%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.08%
H: 0.59%
C: -0.62%
fda biosimilar application license
Recombinant Adeno-Associated Virus (rAAV) Technology Pioneered by AskBio's Dr. Jude Samulski is Key Component of All FDA Approved AAV Gene Therapeutics
Published: 2022-12-20 (Crawled : 23:00) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.18%
H: 0.61%
C: 0.38%
fda approved technology virus therapeutics
Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA
Published: 2022-07-25 (Crawled : 06:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 3.12%
H: 0.06%
C: 0.06%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.06%
H: 0.31%
C: 0.19%
fda biosimilar ema sclerosis multiple sclerosis
Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors
Published: 2022-06-22 (Crawled : 00:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.3%
H: 0.0%
C: 0.0%
fda novartis approval tafinlar
FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
Published: 2022-05-27 (Crawled : 23:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
kymriah fda novartis car-t therapy
FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)
Published: 2022-04-06 (Crawled : 01:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.37%
H: 0.06%
C: 0.06%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.78%
H: 2.05%
C: 2.01%
vijoice treatment fda novartis
Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer
Published: 2022-03-24 (Crawled : 01:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.47%
H: 0.0%
C: -1.11%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.71%
H: 0.0%
C: 0.0%
novartis treatment fda therapy cancer prostate cancer
Novartis Cosentyx® receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis
Published: 2021-12-22 (Crawled : 01:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.23%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.56%
H: 0.43%
C: -0.15%
cosentyx novartis treatment fda fda approval approval children
Alnylam Comments on FDA Approval of Leqvio®, the First siRNA (RNAi Therapeutic) Approved to Reduce LDL-C
Published: 2021-12-22 (Crawled : 23:00) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.55%
H: 0.99%
C: 0.92%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -5.24%
H: 2.44%
C: -0.93%
leqvio fda fda approval approval
FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year
Published: 2021-12-22 (Crawled : 23:00) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.55%
H: 0.99%
C: 0.92%
leqvio novartis fda cholesterol
Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA
Published: 2021-12-20 (Crawled : 23:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.56%
H: 0.3%
C: 0.19%
fda application license biosimilar
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
NYC 4 | $5.91 -4.83% 14.38% 770
|
Finance
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
DEO | News | $140.76 -0.02% 8.27% 560K
|
Consumer Non-Durables
KUKE | $2.88 2.49% 7.64% 360K
|
LYT | $4.22 4.72% 5.62% 1.4M
|
SYY | $76.73 1.44% 5.49% 2.5M
|
Distribution Services
TWI | $11.53 0.96% 4.94% 330K
|
Producer Manufacturing
BTCM | $1.99 -6.13% 4.52% 75K
|
Arts, Entertainment, and Recrea...
MPLN | $0.6502 -11.74% 4.51% 2.2M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.